Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has completed the double-blind study SL0026 \[NCT01449071\] or terminated prematurely at Week 8 or later in SL0026 \[NCT01449071\] due to lack of efficacy
Women of childbearing potential must agree to use an acceptable method of birth control/Written Informed Consent
You may not be if
Subjects with active, severe SLE disease activity which involves the renal system and active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring British Isles Lupus Assessment Group Index (BILAG) level A
Subjects with concurrent relevant medical conditions like defined chronic infections or high risk of new significant infections
Substance abuse or dependence
Significant hematologic abnormalities
History of malignant cancer
Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion
Clareo Health | Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects
